Rocket Pharmaceuticals, Inc.
Price Action
Technical Summary
EMERGING TRENDRocket Pharmaceuticals, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is weak (RS Rating: 37), showing significant lag compared to the market leaders. Earnings growth of 25% provides fundamental context to the price action. Investors should exercise caution due to high volatility (80% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $2.93 | +18.23% | ABOVE |
| 50 SMA | $3.30 | +4.97% | ABOVE |
| 100 SMA | $3.66 | -5.38% | BELOW |
| 150 SMA | $3.58 | -3.32% | BELOW |
| 200 SMA | $3.54 | -2.34% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is RCKT in an uptrend right now?
RCKT has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is RCKT overbought or oversold?
RCKT's RSI (14) is 61. The stock is in neutral territory, neither overbought nor oversold.
Is RCKT outperforming the market?
RCKT has a Relative Strength (RS) Rating of 37 out of 99. RCKT is currently lagging the broader market.
Where is RCKT in its 52-week range?
RCKT is trading at $3.46, which is 63% of its 52-week high ($5.45) and 35% above its 52-week low ($2.40).
How volatile is RCKT?
RCKT has a Beta of 1.92 and 52-week volatility of 80%. It's more volatile than the S&P 500 - expect bigger swings.